PDSB
PDS Biotechnology CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$55.26M
P/E Ratio
—
EPS
$-0.74
Beta
1.19
52W High
$1.92
52W Low
$0.51
50-Day MA
$0.69
200-Day MA
$0.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham Park, New Jersey.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-31.48M |
| Operating Margin | 0.00% |
| Return on Equity | -244.20% |
| Return on Assets | -52.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-4.02 |
| Price-to-Book | 3.82 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $55.82M |
| Float | $51.48M |
| % Insiders | 2.53% |
| % Institutions | 14.24% |
Analyst Ratings
Consensus ($7.50 target)
2
BuyData last updated: 4/9/2026